Related Experiment Video
Updated: Oct 10, 2025

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
Published on: June 8, 2022
The management of lupus nephritis as proposed by EULAR/ERA 2019 versus KDIGO 2021
Hans-Joachim Anders1, Jerome Loutan1, Annette Bruchfeld2,3
1Division of Nephrology, Medizinische Klinik und Poliklinik IV, Klinikum der Universität, Munich, Germany.
Insights
The European League for Rheumatism (EULAR) and Kidney Disease: Improving Global Outcomes (KDIGO) released updated lupus nephritis (LN) guidelines. While mostly consistent, key differences exist in managing lupus podocytopathies and specific treatment scenarios.
Area of Science:
- Nephrology
- Rheumatology
- Immunology
Background:
- Updated lupus nephritis (LN) management guidelines were released in 2019 by EULAR/ERA and in 2021 by KDIGO.
- These guidelines address the increasing complexity of managing LN, a significant autoimmune kidney disease.
Purpose of the Study:
- To review and compare the 2019 EULAR/ERA and 2021 KDIGO guidelines for lupus nephritis management.
- To identify and clarify discrepancies between the two sets of guidelines to aid clinical practice.
Main Methods:
- Comparative analysis of recommendations from the EULAR/ERA (2019) and KDIGO (2021) lupus nephritis guidelines.
- Focus on areas of consistency, negligible differences, and relevant distinctions in management strategies.
Main Results:
- High consistency observed in recommendations for kidney biopsy indications, interpretation, treatment targets, hydroxychloroquine dosing, initial therapy for active LN, and management in pregnancy, pediatrics, and kidney failure.
- Key differences identified in the recognition of lupus podocytopathies, steroid dosing, drug preferences, maintenance therapy, treatment of pure class V LN, recurrent LN, alternative drug options, and thrombotic microangiopathy work-up.
Conclusions:
- Both guideline documents offer excellent guidance for lupus nephritis management.
- Clarifying the identified differences is crucial to prevent confusion and ensure optimal patient care in complex LN cases.
Abstract:
In 2019 and 2021, the European League for Rheumatism (EULAR) jointly with the European Renal Association (ERA) and the Kidney Disease: Improving Global Outcomes (KDIGO), respectively, released updated guidelines on the management of lupus nephritis (LN). The Immunology Working Group of the ERA reviewed and compared both updates. Recommendations were either consistent or differences were of negligible clinical relevance for: indication for kidney biopsy, kidney biopsy interpretation, treatment targets, hydroxychloroquine dosing, first-line initial immunosuppressive therapy for active class III, IV (±V) LN, pregnancy in LN, LN in paediatric patients and LN patients with kidney failure. Relevant differences in the recommended management relate to the recognition of lupus podocytopathies, uncertainties in steroid dosing, drug preferences in specific populations and maintenance therapy, treatment of pure class V LN, therapy of recurrent LN, evolving alternative drug options and diagnostic work-up of thrombotic microangiopathy. Altogether, both documents provide an excellent guidance to the growing complexity of LN management. This article endeavours to prevent confusion by identifying differences and clarifying discrepancies.
Related Concept Videos
Nephrotic Syndrome III : Nursing Management
Chronic Kidney Disease III: Interprofessional Care
Nephrotic Syndrome II : Assessment and Medical Management
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Acute Kidney Injury V: Interprofessional Care
Acute Kidney Injury VI: Nursing Management

